Tejara Capital Ltd Sells 37,415 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Tejara Capital Ltd lessened its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 5.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 612,850 shares of the company’s stock after selling 37,415 shares during the quarter. scPharmaceuticals accounts for approximately 1.4% of Tejara Capital Ltd’s portfolio, making the stock its 20th largest position. Tejara Capital Ltd owned about 1.22% of scPharmaceuticals worth $2,169,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Thrivent Financial for Lutherans boosted its holdings in scPharmaceuticals by 1.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after acquiring an additional 14,866 shares during the last quarter. King Luther Capital Management Corp lifted its holdings in scPharmaceuticals by 0.9% during the third quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after purchasing an additional 20,650 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in scPharmaceuticals during the third quarter valued at about $57,000. BNP Paribas Financial Markets lifted its holdings in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares during the last quarter. Finally, Rubric Capital Management LP increased its position in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after buying an additional 1,250,000 shares during the period. Institutional investors own 89.52% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Monday, March 3rd.

scPharmaceuticals Stock Down 1.0 %

Shares of SCPH opened at $3.00 on Tuesday. The firm has a market cap of $150.12 million, a P/E ratio of -1.58 and a beta of 0.40. The stock has a 50 day simple moving average of $3.32 and a two-hundred day simple moving average of $3.84. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. scPharmaceuticals Inc. has a 1 year low of $2.75 and a 1 year high of $5.95.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.